Pharmaceutical Label Testing: Qualify the Printed Label on Its Container

Pharmaceutical label testing assesses the ability of a defined printed label construction to stay attached and legible on its intended container through various forms of handling, exposure and storage. Hence, evidence, apart from an adhesive datasheet or a successful barcode scan, is required for approval. The basis for approval should be traceable to the sample tested, the test conditions, the result measured and acceptance criteria set prior to the test.

Updated October 2026

Pharmaceutical label testing qualifies a printed construction for a defined container and exposure. Evidence for adhesion, legibility and barcode quality needs to be provided separately. Set acceptance criteria before testing and maintain a specimen-bound report.

What Pharmaceutical Label Testing Should Prove

A pharmaceutical label test assesses a material or printing property under defined conditions. While the scope of the test may include adhesion, retained legibility and barcode quality, approval of the artwork, chemical compatibility and finished-unit labeling remain separate questions when the same pharmaceutical packaging project requires evidence for all of them.

For manufacturing of drugs in the U.S. covered under 21 CFR 211.122(a)-(c), label and packaging materials need to be received under control, representatively sampled, and tested or examined prior to use. Release under such current Good Manufacturing Practice (GMP) controls is dependent on adequate written specifications, and that section doesn’t establish a peel force, wipe count, or grade for barcode for every pharmaceutical label test.

Does pharmaceutical label testing need to be done?

Applicable regulatory requirements and an approved quality system determine which examinations or tests are required. For engineering qualification, a risk-based plan for the intended pack is needed. The acceptable appearance of a sample upon arrival isn’t valid evidence of performance after printing, application and exposure.

Findings in the pharmaceutical industry provide evidence for a defined packaging decision. Patient safety and product integrity also depend on factors outside this material-test matrix; no reductions in labeling errors or product recalls have been measured for this editorial framework. Keep the boundaries visible.

• Material qualification: can the defined construction withstand the intended use?
• Artwork and data approval: does the label contain the approved information?
• Production checks: did the correct label reach the correct pack?
• Compatibility assessment: does the packaging system need separate chemical-suitability evidence?

A 2017 study by Dennis Jenke and coauthors illustrates the last boundary. The abstract made public by the authors describes a model with an LLDPE bottle, a closure, an adhesive label and a foil overpouch, stored for up to 6 months at 40 °C. Label-related substances may migrate into simulated contents without direct label contact. The model migration study abstract doesn’t establish behavior of Guanma stock, every plastic pack or glass vials. Physical durability results alone can’t answer that chemical question.

Approval boundary: Commission the missing assessment when a report answers a different question. Use the pharmaceutical label verification guide, accompanying this document, for approved copy, variable data and release controls.

Define the Label, Container and Packaging Line Before Testing

Test results are for a defined label construction and application, as opposed to a facestock name alone. Hold the material grade, print system, container surface and application settings before deciding on samples. Identify intended storage conditions and handling sequence, so that limits of the test may be recognized by others.

Because different facestock stiffness affects how a label follows a curve, and how an adhesive behaves depends on what surface it contacts, the trial description has to include both physical properties and interface conditions, to be able to interpret the results. Ink, ribbon and overlaminate affect how printed information stands up to contact and rubbing. Because of this, a carton panel, coated glass vial and a plastic container require different descriptions, even if their label dimensions are the same. Naming the same stock doesn’t identify the surface or the geometry of the assembly being tested.

“Testing should represent the conditions that the labeling will be exposed to”

3-Stage Label Qualification Plan

The 3-Stage Label Qualification Plan is an editorial sequence to test the construction, challenge the labeled container and check the production line.

1. Screen the construction. Select relevant material and print tests using identified stock and controlled preparation.
2. Challenge the labeled container. Reproduce surface condition, curvature, exposure and recovery; inspect the complete label.
3. Check the pilot line. Assess dispensing, placement and inspection at the intended operating settings before a production decision.

As an example of the challenges of changing existing technology, let’s take the example of changing the paper label on a medicine vial, to a film label. While the peel report for the film is available, the converter wants to use a different ribbon and a different protective coat. The packaging engineer wants to know the proposed printed label construction on the intended vial, including the vial’s surface treatment. Operators then check release from the liner and placement with the chosen applicator. Quality staff inspect the challenged samples against approved criteria and record any deviation. While the peel report for the film is a good screening tool, it doesn’t cover the new print system, container geometry or the dispensing system, and so other tests are needed to validate the changes.

In trials, provide measurements for throughput in containers/min, label dimensions in mm and application temperature in °C. These values are measured inputs to the process. These measured inputs don’t establish that default settings are adequate or constitute recommended settings. A proposal for PET adhesive film still requires this application definition, especially if labeling machines dispense a revised construction using a liner, feed path or application set-up that’s different from the screening test.

Buyer objection: A supplier may provide only raw stock data. Retain the data supplied, but request the converter and packaging-line evidence needed to substantiate the finished construction.

Check Adhesion and Edge Lift on Small Vials

Peel, initial tack and curved-container hold represent various behavioral characteristics. A suitable peel test method should be used to evaluate the behavior of identified samples against one another under comparable conditions, and the labels must be examined on the vials intended for use. Edge lift, tunneling and overlap are behaviors that are dependent upon construction and geometry. A flat-panel number can’t definitely distinguish applicability.

ASTM D6252/D6252M-98(2025) examines pressure-sensitive labelstock peel adhesion at 90°. Scope allowing surfaces of interest and suggestions for the use of representative substrates notwithstanding, stiff or easily stretching backings can complicate judgment of the measured force. A higher measured force does not necessarily mean that the overall label suitability is better. The suitability of the label still requires application-specific evidence beyond this peel method.

Identities of methods come from the FINAT public test-method list and ASTM public scope. They are a selection map, not a complete procedure. FINAT clearly distinguishes its test methods from performance specifications, and the complete procedure should be sought before a test method is performed.

For biological products within its scope, 21 CFR 610.60(e) requires sufficient container area to remain uncovered for its full length or circumference to permit inspection of the contents. Strong adhesion doesn’t address the blocked inspection area, and the clause gives no minimum window width in mm that can be added to a drawing without assessing the container and its applicable conditions.

Comparison rule: review peel angle and rate, substrate, conditioning and dwell before comparing reports. Record edge lift on the intended container, at the agreed location, with the agreed limit. Context for this failure mode is found in the label flagging explanation.

Challenge Cold-Chain Labels With Real Condensation Conditions

During cold-chain testing of label, the conditions during application must be distinguished from the conditions after the bond has formed. A label applied to a dry container, which has then been placed in a refrigerated condition, hasn’t demonstrated adhesion to a condensation-covered surface. Follow the approved procedures, then inspect the label during exposure and after the prescribed recovery time. The FINAT method list identifies FTM 13 as low temperature adhesion; consult the complete method before using it in a qualification protocol.

Use the product’s approved conditions for the challenge and build the cold-application challenge as part of the study if that’s how the line operates and the study can reproduce the surface state at the point of contact with the label. Include freezing, thawing or sterilizing only if the packaging encounters that. An accelerated challenge should be justified and related to the use; increased challenge severity alone shouldn’t justify the challenge.

• Dry application, later cold exposure: record the initial surface condition and bond-development interval.
• Cold, dry application: verify that preparation and ambient conditions preserve that state.
• Condensation-covered application: document the moisture state and the time between container removal and labeling.
• Recovery inspection: check adhesion, visible defects and legibility at the protocol’s defined inspection points.

Suppose biologic packaging has an approved 2-8 °C storage exposure and its containers are labeled after a controlled transfer into the labeling area. The trial team first documents the container surface temperature and the presence of moisture. If the container is dry, record that condition and compare it with a justified condensation challenge on the material being challenged. Both groups use the same print system with the same application settings. Quality staff document exposure, recovery and observations. These hypothetical trial conditions don’t change the requirements of the approved product. The packaging trial must adhere to those product constraints.

Common mistake: Treating a service temperature claim as proof of cold-surface application is a common mistake. Ask for grade-specific application window and evidence for the tested moisture state. Representative lifecycle exposure, as supported by Susan Ritter, calls for exposure representative of the actual lifecycle; it provides no universal cold dwell or freeze cycle count.

For a 2-8 °C project, the report still needs the measured application temperature, the moisture condition and the exposure duration since recording the storage condition only leaves the bonding step undefined for someone reviewing the evidence later on. Until that sequence is added to the report, the case shouldn’t support this application.

Test Print Against Abrasion and the Actual Wipe Chemical

Print durability testing should challenge the complete printed construction, including any contact and/or rubbing that may occur during use. After defining ink, ribbon, coating and facestock, determine the actual reagent, its concentration, contact time, and mechanical action, then evaluate post-exposure quality of the critical information and barcodes, rather than accept an unchanged blank label as evidence.

The public scope of ASTM D5264-98(2019) describes laboratory comparison of printed material abrasion by means of a Sutherland rub tester or similar. Its flat-substrate scope and agreed comparison conditions are the focus of interest. FINAT’s spot and immersion chemical tests address different exposure conditions. Tests for ink adhesion and ink rub are also different test questions.

A wipe trial should define the actual agent by specifying the product or composition, concentration, wetting, contact period, wipe material and the action done to the wipe. The result of this trial should be compared to the approved acceptance criteria for the defined exposure, not to an undefined resistance claim. Choose an endpoint before the test: text loss, smearing, color transfer, protective layer damage, or a reduction in symbol grade. An alcohol-resistant claim doesn’t give any of the above-mentioned conditions by itself. Define the information that a pharmacist and other healthcare professionals need to read after being handled, and then evaluate if it remains legible against the approved reference, not by a general impression that the artwork looks acceptable.

A converter offers a new thermal-transfer ribbon to print variable data on an existing label. The stock and art remain the same. However, the expiry date smears after a representative cleaning exposure. The buyer asks if the stock is defective. The engineer breaks the question into two parts: the ink-adhesion check is with regard to the Print-to-label interface; the wipe test is toward the printed system under that reagent and action; the test report should indicate which question was actually addressed. A controlled comparison would keep the face-stock and printer setting identified, modify the proposed ribbon, and control (save) samples prior and after exposure. The focus is on the system that was exposed to the test condition. Neither a successful dry-rub test nor an untouched drug name would be an acceptable substitute for legible expiry data after contact with the test condition.

A dated example shows why the print system needs its own identity: Steve Katz’s October 2026 DNP ribbon report describes a supplier launch aimed at alcohol-exposed healthcare printing. It reports product claims, not independent proof for another manufacturer’s label construction.

Buyer objection: In the absence of printed samples and the exposure report, request these records to establish whether the supplier tested the printed construction rather than only unprinted stock. If the construction is changed by the use of a chemical-resistant overlaminate, it shouldn’t automatically be considered evidence for every ink and reagent.

Verify Barcode Quality After Exposure

Tests for verifying barcodes require separate records for decoding, approved data and print quality. A test scan shows the decoded information for the barcode in question under the test conditions of the scanner. Because a verifier evaluates a printed symbol against the requirements, some symbols may still be decoded under the test conditions of the scanner, thus repeat the pertinent checks after exposure if the symbol is subject to abrasion, distortion or contamination that may affect the print quality.

Guidance on creating quality-plans for barcode assessment from GS1 identifies ISO/IEC 15416 for linear symbols and ISO/IEC 15415 for two-dimensional symbols. The grade required of symbols depends on the application. While specifying and reporting verifier aperture and wavelength is required, bare letter grades are not sufficient to fully describe the outcome of an assessment.

Can pharmaceutical labels include barcodes or variable data?

Pharmaceutical labels can embed barcodes and variable data as permitted by the approved design and applicable requirements. Other elements such as serial number, lots and expiry date need approved data, content and retained print quality. As such, reference the approved data, record the inspection, and examine human readable information, if any, in the approved design.

For 2D barcodes, like DataMatrix codes, describe the use case and scanning environment of the symbol. GS1’s retail 2D verification explanation clarifies the distinction between scanner and verifier. Their Retail Acceptance Tables aren’t universal pharmaceutical limits; unique identifiers and anti-counterfeiting features need their own approved data rules.

Report decision: Measurement settings are requested when two different grades are given in separate reports. Keep pre-exposure and post-exposure results for same specimen identities. Software inspection records should indicate what has been checked. A beep can’t demonstrate the entire evidence chain; therefore, automation and a beep can’t be considered exhaustive.

Use a 7-Check Label Test Matrix and Record the Decision

An effective qualification matrix associates each failure mode with a test method, controlled variables, an observed result and approved acceptance criteria. Decide responsibility before testing. Classify each report as applicable, needing supplementation or out-of-scope. Don’t treat every marked pass as interchangeable evidence for the proposed package or a variant that’s being qualified.

7-Check Label Test Matrix

The 7-check Label Test Matrix is an editorial planning tool to link fail modes of printed and processed material to the evidence required for making a defined qualification decision.

Framework basis: The basis for the framework is public FINAT and ASTM methodology scopes, GS1 verification guidance and Ritter’s lifecycle qualification approach. The seven check count is editorial organization. Add other product-related chemical compatibility, tamper evidence or inspection window assessments, outside the scope of this material test matrix.

21 CFR 211.160 requires that appropriate specifications, sampling plans and procedures, along with changes to these, be reviewed and approved by the quality control unit, within the scope of that regulation. Because the samples must be representative and adequately identified, sample numbers and acceptance criteria should be determined by that controlled process; a sample count isn’t assigned by the matrix.

Specimen-to-Report Evidence Sheet

The Specimen-to-Report Evidence Sheet is a handoff record that enables a reviewer to correlate a test result to the actual construction, container and decision it represents.

When not to approve the proposed construction

While a report describes the behavior of a system, a material decision should be held when it covers a different adhesive, print system or container. A matched specimen set and a controlled comparison should be requested. A certificate of analysis may define an agreed lot check, but it can’t prove a lifecycle property that was never tested. Separate material certifications from evidence of the performance of the printed label. For an audit, retain the electronic records and associated specimen images in a controlled repository with the protocol revision and decision so a reviewer can trace the reported result without treating the storage location as proof of validity.

Supplement when construction matches but critical exposure is missing. A cold-storage result leaves condensation-covered application unresolved. A barcode decode leaves formal quality verification unresolved. A report from an accredited lab still needs the correct method and scope; Greg Hrinya’s 2024 AD Procerta report is about Avery Dennison’s service and supplies no accreditation claim for Guanma.

Finished unit controls should be active after qualification. Correct-label checks during finishing, and representative completed-unit visual examination and batch production or control records are separately addressed in 21 CFR 211.134. A material report can’t attest to those checks. The QC staff should record unresolved items, the responsible individual, and what evidence is needed to make a release decision. Additional evidence should be provided especially if sample approval is offered as evidence for a finished products release with different construction or exposure history.

Send Pharmaceutical Companies a Traceable Sample and Change-Control Brief

Suppliers should define the specimen for pharmaceutical companies, stock manufacturers and converters the same way. Identify who provides the material, who prints it, and who approves it. Agree how construction or process changes will be communicated and how and when evidence should be provided to support those changes, and identify the specific requirements that a matched supplier report must address before it supports the decision.

21 CFR 211.184 requires shipment identity and quantity, supplier name, supplier lot if known, receipt, test results and conclusions, in its records. A good procurement handoff captures these identities for traceability, while keeping the records mandated by the regulation distinct from the editorial sheet this blog is focused on. Use sample to report fields to validate the evidence match, and compare candidate materials, while retaining regulated approval decisions with the authorized quality function.

Guanma declares itself as a manufacturer of self-adhesive paper and film label materials. Its pharmaceutical labelstock offering includes PET and PP synthetic paper and coated paper. Send the container substrate, dimensions, printing process, line speed, and exposure, when requesting candidate samples. These statements don’t create an accredited pharmaceutical laboratory or approval of a specific drug pack.

Handoff decision: Evidence is compared; engineering defines test article, and quality approves scope. A request to produce compliant labels requires the defined requirements and those functions and roles, not an assurance by the supplier.

Keep Barcode Change Dates Separate From Test Approval

A future identifier change should enter packaging change control with its own dates and impact assessment. FDA published an NDC and drug-label barcode final rule in March 2026, but its effective date is March 7, 2033. The change does not create an immediate 2026 material-testing deadline or a universal barcode grade, so buyers should separate FDA’s implementation milestones from the test conditions used to evaluate the current label construction.

The March 5, 2026 final rule implements a uniform 12-digit format for the FDA assigned national drug code. FDA’s NDC format summary indicates that the effective date is March 7, 2033, and clarifies FDA assigned codes from formats used for other purposes. Take relevant transition provisions for the actual product and labeling program; publication and implementation are different milestones.

For future changes involving the layout or data content of artwork, assess the impact of changes to the placement, size, or print settings of encoded data. More content may not always fit in the same space with the same measured quality. Keep the approved reference and identify the print file and qualify the symbol with respect to its intended packaging. Don’t take for granted an unaltered adhesive means the entire label change is irrelevant.

• Record the applicable regulatory milestone and responsible regulatory reviewer.
• Identify the affected artwork, encoded fields and electronic system interfaces.
• Assess whether printing or application changes require additional qualification.
• Retain the approved revision and the evidence used for the change decision.

Planned boundary: The rule covers qualifying barcode formats and product identifiers. It doesn’t cover a new peel or abrasion pass value. DSCSA product identifier requirements, and other labeling duties, warrant a separate applicability review. A regulatory submission or change record shouldn’t rely on this material-test matrix to show satisfaction of those requirements.

Pharma buyers can prepare a controlled change list without discarding usable evidence because a rule was published. Re-assess the affected construction, printing and data elements when the proposed change is defined. Keep unrelated material results and their original scope and version.

Frequently Asked Questions

Technical scope: the matrices are editorial planning aids based on public regulations, summaries of methods, and attributed engineering and scientific guidance. They aren’t test results, complete standard procedures, or product approvals. Guanma hasn’t provided proprietary pharmaceutical trial data for this article. The drug manufacturer’s authorized functions are responsible for ensuring the approved requirements and supporting evidence for the product.

Related Articles

• Label durability testing standards and method scope
• Sample qualification and batch acceptance
• PET versus BOPP film label selection
• Guanma label-material manufacturing profile